OLEMA PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 4.42 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 915.77K shares, a 20.18% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 3.50M shares, a 0.44% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 290.60K shares, a 60.29% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 490.80K shares, a 116.88% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 5.03M shares, a 44.59% increase from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 3.48M shares, a 35.39% increase from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 2.57M shares, a 21.99% decline from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 3.29M shares, a 153.47% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 915.77K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | 4.42M shares 10-Q · filed 2026-08-10 | 4.71M shares derived: sum of 3 quarters · filed 2026-08-10 | 5.20M shares derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | 3.50M shares 10-Q · filed 2026-05-12 | 3.79M shares derived: sum of 2 quarters · filed 2026-05-12 | 4.28M shares derived: sum of 3 quarters · filed 2026-05-12 | 5.05M shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 290.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 781.40K shares derived: sum of 2 quarters · filed 2026-03-16 | 1.54M shares derived: sum of 3 quarters · filed 2026-03-16 | 5.03M shares 10-K · filed 2026-03-16 |
| 2025-09-30 | 490.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 1.25M shares derived: sum of 2 quarters · filed 2025-11-10 | 4.74M shares 10-Q · filed 2025-11-10 | 4.92M shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 762.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 4.25M shares 10-Q · filed 2025-08-11 | 4.43M shares derived: sum of 3 quarters · filed 2025-08-11 | 4.66M shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 3.49M shares 10-Q · filed 2025-05-13 | 3.67M shares derived: sum of 2 quarters · filed 2025-05-13 | 3.89M shares derived: sum of 3 quarters · filed 2025-05-13 | 4.43M shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 181.30K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 407.60K shares derived: sum of 2 quarters · filed 2025-03-18 | 948.10K shares derived: sum of 3 quarters · filed 2025-03-18 | 3.48M shares 10-K · filed 2025-03-18 |
| 2024-09-30 | 226.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 766.80K shares derived: sum of 2 quarters · filed 2024-11-12 | 3.30M shares 10-Q · filed 2024-11-12 | 3.51M shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 540.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 3.07M shares 10-Q · filed 2024-08-06 | 3.28M shares derived: sum of 3 quarters · filed 2024-08-06 | 3.41M shares derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | 2.53M shares 10-Q · filed 2024-05-08 | 2.74M shares derived: sum of 2 quarters · filed 2024-05-08 | 2.87M shares derived: sum of 3 quarters · filed 2024-05-08 | 3.11M shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 208.37K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | 334.77K shares derived: sum of 2 quarters · filed 2024-03-11 | 579.76K shares derived: sum of 3 quarters · filed 2024-03-11 | 2.57M shares 10-K · filed 2024-03-11 |
| 2023-09-30 | 126.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 371.39K shares derived: sum of 2 quarters · filed 2023-11-07 | 2.36M shares 10-Q · filed 2023-11-07 | 2.52M shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 244.99K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 2.23M shares 10-Q · filed 2023-08-08 | 2.40M shares derived: sum of 3 quarters · filed 2023-08-08 | 2.60M shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 1.99M shares 10-Q · filed 2023-05-09 | 2.15M shares derived: sum of 2 quarters · filed 2023-05-09 | 2.35M shares derived: sum of 3 quarters · filed 2023-05-09 | 2.62M shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 161.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | 361.45K shares derived: sum of 2 quarters · filed 2023-03-09 | 629.99K shares derived: sum of 3 quarters · filed 2023-03-09 | 3.29M shares 10-K · filed 2023-03-09 |
| 2022-09-30 | 199.95K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 468.49K shares derived: sum of 2 quarters · filed 2022-11-08 | 3.13M shares 10-Q · filed 2022-11-08 | 3.40M shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 268.54K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 2.93M shares 10-Q · filed 2022-08-09 | 3.20M shares derived: sum of 3 quarters · filed 2022-08-09 | 3.35M shares derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | 2.66M shares 10-Q · filed 2022-05-09 | 2.93M shares derived: sum of 2 quarters · filed 2022-05-09 | 3.08M shares derived: sum of 3 quarters · filed 2022-05-09 | 3.49M shares derived: sum of 4 quarters · filed 2022-05-09 |
| 2021-12-31 | 267.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | 417.20K shares derived: sum of 2 quarters · filed 2022-02-28 | 830.63K shares derived: sum of 3 quarters · filed 2022-02-28 | 1.30M shares 10-K · filed 2022-02-28 |
| 2021-09-30 | 149.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 562.93K shares derived: sum of 2 quarters · filed 2021-11-10 | 1.03M shares 10-Q · filed 2021-11-10 | |
| 2021-06-30 | 413.43K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | 882.23K shares 10-Q · filed 2021-08-10 | ||
| 2021-03-31 | 468.80K shares 10-Q · filed 2021-05-11 | |||
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 0.00 shares derived: sum of 2 quarters · filed 2021-11-10 | 0.00 shares 10-Q · filed 2021-11-10 | |
| 2020-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | 0.00 shares 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | 0.00 shares 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |